Literature DB >> 27969572

Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis.

Jennifer M Hanify1, Lori H Dupree2, Donald W Johnson3, Jason A Ferreira4.   

Abstract

PURPOSE: Critically ill patients who develop sepsis may be at a higher risk of venous thromboembolism (VTE) prophylaxis failure; however, studies in this population are limited. The objective of this study was to identify the incidence of VTE prophylaxis failure in this population.
METHODS: This retrospective review of patients admitted to the intensive care unit between February 2013 and September 2015 included patients who were diagnosed with sepsis and received heparin or enoxaparin VTE prophylaxis.
RESULTS: Of the 355 patients included, 42 (12.5%) developed a VTE. Acute respiratory distress syndrome (ARDS) (31% vs 16.7%, P = .0272) and higher positive end expiratory pressure (10 vs 8, P = .0066) were associated with increased risk of VTE prophylaxis failure. Logistic regression identified ARDS an event risk factor (odds ratio, 2.58; 95% confidence interval, 1.22-5.42). The VTE was associated with an increased intensive care unit (14 vs 9 days, P = .01) and hospital length of stay (26 vs 15 days, P < .0001). The median time from sepsis diagnosis to VTE event was 9 days (interquartile range, 5-13).
CONCLUSION: Critically ill patients with sepsis had a high rate of VTE prophylaxis failure with ARDS being identified as a risk factor for VTE prophylaxis failure.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute respiratory distress syndrome; Anticoagulant; Critically ill; Sepsis; Thromboprophylaxis; Venous thromboembolism

Mesh:

Substances:

Year:  2016        PMID: 27969572     DOI: 10.1016/j.jcrc.2016.10.002

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  12 in total

Review 1.  Thrombotic Risk and Covid-19: Review of Current Evidence for a Better Diagnostic and Therapeutic Approach.

Authors:  Raquel López-Reyes; Grace Oscullo; David Jiménez; Irene Cano; Alberto García-Ortega
Journal:  Arch Bronconeumol       Date:  2020-08-31       Impact factor: 4.872

2.  Utility of D-dimer as a Prognostic Factor in SARS CoV2 Infection: A Review.

Authors:  Pramod Theetha Kariyanna; Lyudmila Aurora; Apoorva Jayarangaiah; Vivek Yadav; Naseem A Hossain; Nasrin Akter; Moro O Salifu; Isabel M McFarlane
Journal:  Am J Med Case Rep       Date:  2020-06-22

3.  Venous thromboembolism and COVID-19.

Authors:  L Bertoletti; F Couturaud; D Montani; F Parent; O Sanchez
Journal:  Respir Med Res       Date:  2020-04-28

Review 4.  Thrombosis and Haemostasis challenges in COVID-19 - Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review.

Authors:  Laura Mazilu; Niki Katsiki; Taxiarchis Konstantinos Nikolouzakis; Minas I Aslanidis; George Lazopoulos; Dimitrios Kouretas; Aristidis Tsatsakis; Andra-Iulia Suceveanu; Anca-Pantea Stoian; Irinel-Raluca Parepa; Felix Voinea; Adrian Paul Suceveanu; Andreea Letiția Arsene; Bruno Ștefan Velescu; Cosmin Vesa; Cornelia Nitipir
Journal:  Food Chem Toxicol       Date:  2021-01-06       Impact factor: 5.572

5.  Thromboprophylaxis in COVID-19: Anti-FXa-the Missing Factor?

Authors:  Tina Dutt; David Simcox; Colin Downey; Daniella McLenaghan; Charlotte King; Manish Gautam; Steven Lane; Hassan Burhan
Journal:  Am J Respir Crit Care Med       Date:  2020-08-01       Impact factor: 21.405

Review 6.  Coagulopathy in COVID-19.

Authors:  Toshiaki Iba; Jerrold H Levy; Marcel Levi; Jecko Thachil
Journal:  J Thromb Haemost       Date:  2020-07-21       Impact factor: 16.036

7.  Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis.

Authors:  Syed Shahzad Hasan; Sam Radford; Chia Siang Kow; Syed Tabish Razi Zaidi
Journal:  J Thromb Thrombolysis       Date:  2020-11       Impact factor: 2.300

8.  Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.

Authors:  Kevin A Bobeck; Arthur W Holtzclaw; Tara E Brown; Paul A Clark
Journal:  A A Pract       Date:  2020-04

9.  Utility of D-dimers and intermediate-dose prophylaxis for venous thromboembolism in critically ill patients with COVID-19.

Authors:  Maxime G Zermatten; Olivier Pantet; Francisco Gomez; Antoine Schneider; Marie Méan; Lucia Mazzolai; Olivier Hugli; Pierre-Alexandre Bart; Matthaios Papadimitriou-Olivgeris; Lorenzo Alberio
Journal:  Thromb Res       Date:  2020-08-21       Impact factor: 3.944

10.  Venous and arterial thromboembolic disease in COVID-19.

Authors:  J Ten Berg
Journal:  J Thromb Thrombolysis       Date:  2021-07-13       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.